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Gerard van Grootheest, MSc; Mieke Cabout, MSc; Ulrich Hegerl, PhD; Margalida Gili, PhD; Matthew Owens, PhD; Marjolein Visser, PhD;
for the MooDFOOD Prevention Trial Investigators
IMPORTANCE Effects of nutritional interventions on the prevention of major depressive
disorder (MDD) in overweight adults are unknown.
OBJECTIVE To examine the effect of 2 nutritional strategies (multinutrient supplementation,
food-related behavioral activation therapy) and their combination for prevention of a new
MDD episode in overweight adults with subsyndromal depressive symptoms.
DESIGN, SETTING, AND PARTICIPANTS This multicenter 2 × 2 factorial randomized clinical trial
included overweight adults (body mass index, 25-40) with elevated depressive symptoms
(Patient Health Questionnaire-9 [PHQ-9] scores 5) and no MDD episode in the past 6
months from 4 European countries. A total of 1025 adults were randomized (July 30,
2015-October 12, 2016) and followed up for 1 year (October 13, 2017).
INTERVENTIONS Daily multinutrient supplements (1412-mg omega-3 fatty acids, 30-μg
selenium, 400-μg folic acid, and 20-μg vitamin D3 plus 100-mg calcium) vs placebo and 21
individual or group therapy sessions vs none (blinded to researchers) for 1 year. Participants
were allocated to placebo without therapy (n = 257), placebo with therapy (n = 256),
supplements without therapy (n = 256), and supplements with therapy (n = 256).
MAIN OUTCOME AND MEASURES Cumulative 1-year onset of MDD via the Mini International
Neuropsychiatric Interview at 3, 6, and 12 months. Logistic regression using effect-coded
variables (−1 indicating control, 1 indicating intervention) evaluated intervention effects both
individually and in combination (interaction) on MDD onset.
RESULTS Among 1025 participants (mean age, 46.5 years; 772 women [75%]; mean BMI, 31.4), 779
(76%) completed the trial. During the 12-month follow-up, 105 (10%) developed MDD: 25 (9.7%)
patients in the placebo without therapy, 26 (10.2%) in the placebo with therapy, 32 (12.5%) in the
supplement without therapy, and 22 (8.6%) in the supplement with therapy group. None of the
treatment strategies affected MDD onset. The odds ratio (OR) for supplements was 1.06 (95% CI,
0.87-1.29); for therapy, 0.93 (95% CI, 0.76-1.13); and for their combination, 0.93 (95% CI, 0.76-1.14;
P for interaction, .48). One person in the supplementation with therapy group, died. Twenty-four
patients in each of the placebo groups and 24 patients in the supplementation with therapy group
were hospitalized, and 26 patients in the supplementation-only group were hospitalized.
CONCLUSIONS AND RELEVANCE Among overweight or obese adults with subsyndromal
depressive symptoms, multinutrient supplementation compared with placebo and
food-related behavioral activation therapy compared with no therapy did not reduce
episodes of major depressive disorder during 1 year. These findings do not support the use of
these interventions for prevention of major depressive disorder.
TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02529423
JAMA. 2019;321(9):858-868. doi:10.1001/jama.2019.0556
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M ajor depressive disorder (MDD) is a common psychi-atric disorder (lifetime prevalence, 17%),1 ranking asthe second leading contributor of years lived with
disability.2 Prevention may offer an important opportunity to
reduce the global disease burden of MDD.3
One preventive strategy for MDD might be to modify diet.
Prospective studies have found that better adherence to higher
quality diets is associated with reduced future onset of de-
pressive symptoms.4 Food-related behaviors, like unhealth-
ful eating styles,5 have been cross-sectionally related to in-
creased depressive symptoms. Recent randomized clinical
trials (RCTs) found that dietary improvement strategies re-
duced depressive symptoms in depressed adults relative to con-
trol conditions,6,7 but there remains a clear lack of RCTs test-
ing dietary strategies to prevent depression.8
Similarly, observational studies have suggested that lower
levels of specific nutrients (eg, omega-3 polyunsaturated fatty
acids, folic acid, vitamin D, selenium) are related to higher lev-
els of depressive symptoms.9,10 Some—but not all—nutritional
supplement intervention studies have indicated that nutrient
supplementation may reduce depressive symptoms in those
with MDD.11
To date, few experimental studies have directly evalu-
ated the effect of changing diet, food-related behavior, or nu-
trients on preventing MDD8,12 and none to our knowledge have
specifically targeted overweight and obese individuals, who
are a particularly relevant population, given their increased risk
of MDD and the key role of diet in these conditions.13 There-
fore, the MooDFOOD depression prevention trial examined the
effect of 2 different nutritional strategies (multinutrient supple-
mentation, food-related behavioral activation therapy) and
their combination for prevention of a new MDD episode in over-
weight people with subsyndromal depressive symptoms.
Methods
Study Design
This study was a 2 × 2 factorial RCT performed between July
30, 2015, and October 13, 2017, in 4 European countries
(Germany, Spain, United Kingdom, and the Netherlands). For
full details of trial design and protocol see Roca et al14 and
Supplement 1. For the statistical analysis plan, see Supple-
ment 2. Ethics approval was provided by the human research
ethics boards of the 4 study sites. All participants provided writ-
ten informed consent. This article reports on primary and sec-
ondary mental health outcomes as assessed up to 12 months.
Recruitment and Eligibility Criteria
Participants were recruited to participate in a study investi-
gating new strategies to improve mood and well-being through
changes in diet and lifestyle by the study sites (located in
Leipzig, Germany; Palma de Mallorca, Spain; Exeter, United
Kingdom; and Amsterdam, the Netherlands). Main eligibility
criteria were age between 18 and 75 years, body mass index
(BMI, calculated as weight in kilograms divided by height in
meters squared) between 25 and 40, having at least mild de-
pressive symptoms as operationalized by Patient Health Ques-
tionnaire (PHQ-9) scores of 5 or higher15 but having no cur-
rent MDD episode in past 6 months (Mini International
Neuropsychiatric Interview 5.0 [MINI 5.0]).16 (See eAppen-
dix 1 in Supplement 3 for recruitment details and eligibility.)
All eligible participants were invited to visit one of the study
sites for a baseline interview. The interview, physical mea-
surements, blood sampling were conducted by trained re-
search assistants or nurses. Furthermore, participants com-
pleted self-report questionnaires. Follow-up assessments took
place at 3, 6, and 12 months.
Randomization
At the end of the baseline interview, participants were ran-
domized with equal probability to (1) placebo supplements
without therapy; (2) placebo supplements with therapy;
(3) multinutrient supplements without therapy; or (4) mul-
tinutrient supplements with therapy by a permuted block
randomization (block sizes ranging from 8-12; https://www.
sealedenvelope.com). Randomization was stratified by study
site and participants’ lifetime history of depression status
(Figure 1). After randomization, researchers dispensed
supplements to participants according to unique randomiza-
tion codes. Participants, therapists, and researchers were
blinded to supplement allocation. Participants of food-
related behavioral activation intervention therapy were con-
tacted directly by the therapist, ensuring that researchers
assessing follow-up outcomes remained blind to this inter-
vention status. Statistical analyses on the primary outcome
and the reported secondary outcomes in which participants
were analyzed according to their randomization group were
carried out blinded for randomization.
Interventions
Multinutrient Supplements
Patients received either multinutrient supplements (1412 mg
of eicosapentaenoic and docosahexaenoic omega-3 poly-
unsaturated fatty acids [PUFAs]; ratio, 3:1), 30 μg of sele-
nium, 400 μg of folic acid, and 20 μg of vitamin D3 coupled
with 100 mg of calcium) or placebo, each were provided in
2 pills per day, taken daily for 1 year (see eAppendix 2
in Supplement 3 for details).
Key Points
Question What is the effect of multinutrient supplementation and
food-related behavioral activation therapy on prevention of a new
episode of major depressive disorder among overweight or obese
adults with subsyndromal depressive symptoms?
Findings In this 2 × 2 factorial randomized clinical trial that
included 1025 adults, there was no significant difference in
episodes of major depressive disorder over 1 year of follow-up with
multinutrient supplementation vs placebo (54 [10.5%] vs 51
[9.9%]) or with food-related behavioral activation therapy vs no
therapy (48 [9.4%]) vs 57 [11.1%]).
Meaning These findings do not support the use of multinutrient
supplementation or food-related behavioral activation therapy for
prevention of major depressive disorder.
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Figure 1. Flow of Participants Through the MooDFOOD Depression Prevention Trial
5965 Individuals completed online
screening questionnaire
1250 Eligible for baseline measurement
3730 Excluded
1451 BMI <15 or >40
623 Antidepressant use in past 6 mo
591 No contact information
566 PHQ score <5
268 PHQ score missing
220 None of the questions answered
11 Age <18 y or >75 y
462 Excluded (no telephone screening)
523 Excluded
259 Current depressive disorder
97 Antidepressant or psychological therapy
 in the last 6 mo
44 Supplements prescribed or not willing
to stop taking supplements
38 Psychiatric disordera
26 Not prepared to visit study center
18 BMI <25
15 Pregnant or planning to become pregnant
12 Other mood disorder
7 Bariatric surgery
4 Did not understand study information
3 Severe medical disease
225 Excluded (unwilling or not able to participate)
1025 Randomized




256 Included in the primary analysisc
MDD measurement at follow-up
58 Cumulative loss to follow-upb 





198 At month 12
215 At month 3
197 At month 6




256 Included in the primary analysisc
MDD measurement at follow-up
62 Cumulative loss to follow-upb 






194 At month 12
202 At month 3
185 At month 6




256 Included in the primary analysisc
MDD measurement at follow-up
65 Cumulative loss to follow-upb 





191 At month 12
209 At month 3
193 At month 6




257 Included in the primary analysisc
MDD measurement at follow-up
61 Cumulative loss to follow-upb 






196 At month 12
205 At month 3
196 At month 6
2235 Eligible for telephone screening
1773 Completed the telephone screening
a Bipolar disorder, schizophrenia, psychosis, eating disorder, anxiety disorder,
alcohol, drug, or substance addiction.
b Cumulative loss to follow-up is defined as having no MDD measurement at
month 12.
c The primary analysis included all participants according to their randomization
group, including all participants randomized regardless of the intervention
actually received or of study withdrawal. Missing data were multiple imputed.
BMI indicates body mass index; MDD, major depressive disorder; PHQ, Patient
Health Questionnaire.
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Food-Related Behavioral Activation Therapy
Food-related behavioral activation therapy consisted of a
protocol-based intervention that incorporated standard
behavioral activation approaches. Behavioral activation is
effective in depression treatment17 and includes self-
monitoring, functional analysis, and activity scheduling.
Food-related behavioral activation applied these proven
techniques to improve mood by changing dietary habits,
food-related behaviors (eg, snacking), increasing positive
behaviors, and emphasizing a Mediterranean-style diet,
which has been related to reduced depression onset.4
A maximum of 21 sessions were provided (15 individual,
6 group) for 1 year (see eAppendix 3 in Supplement 3). No
active (eg, attention) control condition was provided in
those receiving no therapy.
Outcomes
Primary Outcome
The primary outcome was the 12-month cumulative onset of
an episode of MDD, defined according to standard psychiat-
ric Diagnostic and Statistical Manual of Mental Disorders (Fourth
Edition) criteria and was measured with the depression sec-
tion of the MINI 5.016 at 3, 6, and 12 months.
Secondary Outcomes
Secondary trial outcomes were depression severity (PHQ-9,
range 0-27, with higher values indicating higher severity,15
Inventory of Depressive Symptomatology; IDS30-SR, range
0-84, with higher values indicating higher severity),18 anxi-
ety severity (Generalized Anxiety Disorder 7 Item Scale
[GAD-7], range 0-21, with higher values indicating higher
severity),19 health-related quality of life (utility, EuroQol
instrument [EQ-5D-5L],20 using the value sets for England,21
range 0-1, with higher values indicating better health utility),
eating behavior (3-factor eating questionnaire [TEFQ-R18],
all 3 factors ranging from 0-100, with higher values indicat-
ing poorer eating behavior)22 food behavior, food intake
(Global Allergy and Asthma European Network [GA2LEN]
food frequency questionnaire23), physical activity and
sedentary behavior (short questionnaire to assess health-
enhancing physical activity [SQUASH]24), and body weight
perception (Stunkard et al25). This article reports on the men-
tal health secondary outcomes depression severity (PHQ-9,15
IDS30-SR),18 anxiety severity (GAD-7),19 and utility (EQ-5D-
5L; eAppendix 4 in Supplement 3).20,21 Time to onset of first
MDD episode was included for post hoc analyses.
Other Measures
Good adherence to interventions (attending ≥8 of 21 therapy
sessions, and taking ≥70% of the supplements during the 12
months) was defined a priori. A detailed description of these
and other measures can be found in eAppendixes 5 and 6 in
Supplement 3.
Sample Size
Sample size was based on the primary outcome and
accounted for the 2 × 2 factorial design. At the time the
trial was designed, effective preventive interventions in high-
risk groups were found to reduce the onset of depression by
25% to 50%.3 Assuming a 33% reduction of MDD onset
between active (20% MDD onset) vs control conditions (30%
MDD onset),26,27 392 participants (196 in each of the 4 pos-
sible intervention combinations) were needed to evaluate
the main effect of each of the 2 nutritional interventions
(vs respective control) assuming a 2-sided test at α = .05 and
a power of (1−β) = .90. Assuming a follow-up attrition rate of
22%, 250 participants per intervention combination were
needed. This corresponds to an absolute difference of 10%,
which is consistent with the assumed clinically relevant dif-
ference in depression onset, estimated by consulting clinical
experts and stakeholders (eg, health insurance companies),
reported in a previous depression prevention trial.28
Statistical Methods
Participants were analyzed according to their randomization
group, including all participants randomized regardless
of intervention actually received or study withdrawal. The 2
nutritional interventions were effect coded (−1 indicating
control and 1 indicating intervention) and jointly modeled to
efficiently study main effects and interactions as recom-
mended for factorial designs.29 All analyses were adjusted for
study site and history of MDD. Missing data for the trial end
points were accounted for using multiple imputation under the
missing at random assumption into 100 data sets. Results were
pooled using the Rubin rules.30
Logistic regression analyses were conducted to estimate
effects of the interventions on the primary outcome. Cox pro-
portional hazard modeling was used to study intervention
effects on time to first MDD onset (3, 6, or 12 months for
either MDD onset or last available measurement) as post hoc
analysis. Scaled Schoenfeld residuals were used to test
the proportionality of hazard assumption, which was
met (P > .05). For secondary outcomes, generalized estimat-
ing equations (GEE) longitudinal analysis of covariance
(ANCOVA) with an exchangeable correlation structure was
used,31 modeling outcomes at 3, 6, and 12 months as depen-
dent variables and adjusting for their corresponding baseline
values. Overall follow-up effects (including all follow-up
assessments) and 12-month effects of the interventions for
these secondary follow-up outcomes were tested.31 Because
of the potential for type I error due to multiple comparisons,
findings for analyses of secondary end points should be inter-
preted as exploratory. Effect modification of study site and
history of MDD was investigated with their corresponding
interaction terms with the interventions. Similarly, effect
modification by baseline symptom severity was included as
post hoc analyses.
As GEE are known to be robust for missing data, GEE lon-
gitudinal ANCOVA without multiple imputation was carried
out as sensitivity analyses. A Cohen D value was calculated
for each baseline, 12-month follow-up difference in second-
ary outcome between the intervention groups,32 using mul-
tiple imputed data. Furthermore, complier average causal
effect (CACE) analyses33,34 were carried out with the multiple
imputed data using structural equation modeling within
STATA, to provide an estimate of intervention effects taking
Effect of Behavioral Therapy and Supplements on MDD Among Overweight and Obese Adults Original Investigation Research
jama.com (Reprinted) JAMA March 5, 2019 Volume 321, Number 9 861
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Vrije Universiteit User  on 11/09/2020
Table 1. Baseline Sample Characteristics of the Trial Stratified by Intervention Group



















Men 77 (30.0) 63 (24.6) 63 (24.6) 50 (19.5)
Women 180 (70.0) 193 (75.4) 193 (75.4) 206 (80.5)
Age, y
Mean (SD) 45.7 (13.2) 46.1 (12.8) 47.2 (13.3) 47.1 (12.7)
Median (IQR) 47 (36-55) 47 (37-55) 48 (38-58) 47 (38-56)
Site
Germany 70 (27.2) 67 (26.2) 69 (27.0) 71 (27.7)
United Kingdom 64 (24.9) 63 (24.6) 64 (25.0) 63 (24.6)
Spain 64 (24.9) 64 (25.0) 62 (24.2) 62 (24.2)
The Netherlands 59 (23.0) 62 (24.2) 61 (23.8) 60 (23.4)
Educationa
Low 25 (9.7) 21 (8.2) 31 (12.1) 26 (10.2)
Middle 124 (48.2) 141 (55.1) 120 (46.9) 113 (44.1)
High 108 (42.0) 94 (36.7) 105 (41.0) 117 (45.7)
History of MDD 83 (32.3) 89 (34.8) 88 (34.4) 83 (32.4)
≥2 Episodes 59 (23.0) 53 (20.7) 62 (24.2) 58 (22.7)
Current smoker 53 (20.6) 50 (19.5) 35 (13.7) 47 (18.4)
Alcohol use, median (IQR), drinks/wk 1.0 (0.2-3.7) 1.0 (0.2-3.7) 1.0 (0.2-3.7) 1.0 (0.2-3.7)
Physical activity, median (IQR), h/db 7.8 (6.1-9.5) 7.8 (5.6-10.0) 7.9 (5.9-10.2) 7.5 (5.3-9.7)
BMI, mean (SD) 31.4 (4.1) 31.2 (3.9) 31.3 (4.0) 31.7 (3.9)
Depression severity
PHQ-9c
Mean (SD) 7.3 (4.1) 7.3 (4.4) 7.9 (4.4) 7.1 (4.0)
Median (IQR) 7 (4-10) 6 (4-10) 7 (5-10) 6 (4-9)
IDSd
Mean (SD) 21.3 (9.8) 21.6 (10.5) 22.8 (10.2) 21.4 (9.8)
Median (IQR) 20 (14-27) 21 (13-29) 21 (15-30) 20 (14-28)
Anxiety severitye
Mean (SD) 5.8 (4.4) 6.2 (4.5) 5.7 (3.8) 5.4 (3.8)
Median (IQR) 5 (3-7) 5 (3-9) 5 (3-7) 5 (3-7)
Health utilityf
Mean (SD) 0.87 (0.11) 0.86 (0.13) 0.86 (0.12) 0.86 (0.12)
Median (IQR) 0.88 (0.82-0.94) 0.87 (0.81-0.95) 0.87 (0.81-0.94) 0.88 (0.81-0.94)
MooDFOOD diet score, mean (SD)g 51.7 (7.6) 51.9 (6.9) 51.6 (6.8) 51.4 (6.9)
Prior (multi)-nutrient supplement use 77 (30.0) 86 (33.6) 78 (30.5) 79 (30.9)
Abbreviations: BMI, body mass index, calculated as weight in kilograms divided
by height in meters squared; EQ5D5L, EuroQol 5 dimension 5 level;
GAD-7, Generalized Anxiety Disorder 7; IDS, Inventory of Depressive
Symptomatology; IQR, interquartile range; MDD, major depressive disorder;
PHQ-9, Patient Health Questionnaire 9.
a Low represents no education, primary education, or lower secondary
education; middle, upper secondary education; postsecondary nontertiary
education, short-cycle tertiary education; high, bachelor’s degree or higher
or equivalent level.
b Represents the number of hours per day spent on commuting (walking and
cycling) and on work-related, household, leisure time, and sport activities.
c Higher values (range, 0-27) indicate greater severity (5 indicates mild
depression; 10, moderate depression).
d Higher values (range, 0-84) indicate greater severity (14 indicates mild
depression; 26 , moderate depression).
e Higher values (range, 0-21) indicate greater severity (5 indicates mild
anxiety; 10 moderate anxiety).
f Higher values (range, 0-1) indicate higher health utility (0, death; 1, full health).
Health utility is based on the tariff of England, which is an algorithm that can
be used to attach values to all health states derived from the health-related
quality-of-life EQ5D5L instruments, reflecting a country-specific preference
on health states.
g Higher values (range, 0-77) indicate better adherence to the
Mediterranean-style diet. The median intakes of each of the 11 MooDFOOD
diet score components were vegetables (2.8 times per day), fruit (1.9 times
per day), fish (1.5 times per week), legumes or pulses (1 times per week), meat
(5 times per week), whole grain products (67% of total grains), low-fat dairy
(0.9 times per day), olive oil (33% of total dressings, cooking oils, and fats),
soft drinks (0.14 times per day), processed food (1.6 times per day), and
alcohol (0.14 times per day).
Research Original Investigation Effect of Behavioral Therapy and Supplements on MDD Among Overweight and Obese Adults
862 JAMA March 5, 2019 Volume 321, Number 9 (Reprinted) jama.com
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Vrije Universiteit User  on 11/09/2020
into account good adherence with the interventions, while
retaining the benefits of randomization for both primary and
secondary 12-month follow-up outcomes (eAppendix 7 in
Supplement 3). Analyses were conducted with R (version
3.4.4), using the packages geepack for the GEE analyses and
mice for multiple imputation. The 2-sided significance
threshold was set at P = .05.
Results
Description of Participants
Between July 30, 2015, and October 12, 2016, 5965 individu-
als visited the online screening questionnaire, 2235 partici-
pants fulfilled the key inclusion criteria, 1773 participants
completed the subsequent telephone screening, and 1250
were deemed eligible for the trial. After subsequent exclu-
sion of individuals not willing or able to participate, 1025
adults were randomly allocated to the 4 groups: placebo
without therapy (n = 257), placebo with therapy (n = 256),
multinutrient supplements without therapy (n = 256), and
multinutrient supplements with therapy (n = 256)
(Figure 1). Table 1 shows the baseline characteristics of the
intervention groups.
Follow-up Attrition
The number of participants not taking part in follow-up
assessment were 194 (19%) at 3 months, 254 (25%) at 6
months, and 246 (24%) at 12 months (Figure 1). In total, 239
participants (23%) dropped out before the 12-month
follow-up or before the onset of MDD (the main outcome)
occurred. Missing rates for the primary outcome did not dif-
fer between the 4 intervention groups at 3 months (P = .47),
6 months (P = .62), and 12 months (P = .91). Missing rates for
the secondary outcomes of depressive symptoms, anxiety
symptoms, and health utility scores obtained through self-
report questionnaires were slightly higher: number of indi-
viduals with missing data at baseline was 29 to 32, at 3
months 206 to 211, at 6 months 275 to 278, and at 12 months
268 for these outcomes. These missing rates did not differ
across intervention groups.
Adherence to Interventions
Adherence for each group is described in eAppendix 8 in
Supplement 3. Of all 12-month follow-up participants, pill
weight data indicated that 77% of participants had adherence
of more than 70% to the supplements or placebo. Of those
randomized to the therapy groups, 71% attended 8 or more of
the 21 sessions. A median of 14 of 15 individual sessions were
attended (interquartile range [IQR], 6-15), and a median of 0
of 6 group sessions (IQR, 0-4) were attended, indicating that
adherence to individual sessions was highest.
Onset of MDD
One hundred five participants (10%) developed an MDD
episode during the 12-month follow-up (Table 2): 25 partici-
Table 2. Effect of Supplements and Food-Related Behavioral Activation Therapy on Major Depressive Disorder Onset
No. of Patients No. of Events
No. of Follow-up
Dropoutsa Imputed OR (95% CI)b P Valueb
Primary Outcome: 12-mo MDD Onset
Placeboc 513 51 113 1 [Reference]
Supplementsd 512 54 126 1.06 (0.87-1.29) .57
Food-related behavioral
activation therapy
Noe 513 57 122 1 [Reference]
Yesf 512 48 117 0.93 (0.76-1.13) .47
Supplements by therapyg NA NA NA 0.93 (0.76-1.14) .48





Placebo 4656 51 113 1 [Reference]
Supplements 4488 54 126 1.05 (0.86-1.27) .65
Food-related behavioral
activation therapy
No 4503 57 122 1 [Reference]
Yes 4641 48 117 0.91 (0.75-1.10) .32
Supplements by therapyg NA NA NA 0.91 (0.75-1.11) .36
Abbreviations: HR, hazard ratio; MDD, major depressive disorder; NA, not
applicable; OR, odds ratio.
a No. that did not complete 12 mo follow-up and had no MDD at previous
follow-up measurements.
b Derived from multiple imputed data. Models were adjusted for interventions,
site and history of MDD. Food-related behavioral activation therapy and pills
were effect-coded (−1,1).
c Twenty-five of 257 participants (9.7%) in the placebo without therapy group
and 26 of 256 (10.2%) in the placebo group with therapy.
d Thirty-two of 256 participants (12.5%) in the supplements without therapy
group and 22 of 256 (8.6%) in the supplements without therapy group.
e Twenty-five of 257 participants (9.7%) in the placebo group without therapy
and 32 of 256 (12.5%) in the supplements without therapy group.
f Twenty-six of 256 participants (10.2%) in the placebo with therapy group and
22 of 256 (8.6%) in the supplements with therapy group.
g Interaction between therapy and supplements.
Effect of Behavioral Therapy and Supplements on MDD Among Overweight and Obese Adults Original Investigation Research
jama.com (Reprinted) JAMA March 5, 2019 Volume 321, Number 9 863
© 2019 American Medical Association. All rights reserved.
Downloaded From: https://jamanetwork.com/ by a Vrije Universiteit User  on 11/09/2020
pants (9.7%) receiving placebo alone, 26 (10.2%) receiving
placebo with therapy, 32 (12.5%) receiving supplements
alone, and 22 (8.6%) receiving supplements with therapy.
Considering the main effect of each intervention, the num-
bers of participants who developed MDD were 51 participants
(9.9%; 1.1 per 100 person-months) receiving placebo, 54
(10.5%; 1.2 per 100 person-months) receiving supplements,
57 (11.1%; 1.3 per 100 person-months) not receiving therapy,
and 48 (9.4%; 1.0 per 100 person-months) receiving therapy.
Logistic regression using effect-coded intervention variables
(−1,1) showed no significant effect of supplements (OR, 1.06;
95% CI, 0.87-1.29; P = .57) or food-related behavioral activa-
tion therapy (OR, 0.93, 95% CI, 0.76-1.13; P = .47) or signifi-
cant supplements × therapy interaction (OR, 0.93; 95% CI,
0.76-1.14, P for interaction, .48) on the onset of MDD. There
was no significant effect of supplements (HR, 1.05; 95% CI,
0.86-1.27; P = .65) or therapy (HR, 0.91; 95% CI, 0.75-1.10;
P = .32) or significant supplements × therapy interaction
(HR, 0.91; 95% CI, 0.75-1.11; P for interaction, .36) on the time
to first onset of MDD (Table 2).
Depressive Symptoms, Anxiety Symptoms,
and Health Utility
Figure 2 shows boxplots and means of the secondary out-
come scores at baseline and at 3, 6, and 12 months stratified
by food-related behavioral activation and supplement groups
(see eAppendix 9 in Supplement 3 for figure stratified by the
4 intervention combinations). There were no significant supple-
ment × food-related behavioral activation therapy interac-
tions for any of the secondary outcome scores (P values for in-
teraction ranged from .41 to .98). Table 3 presents effects on
secondary outcomes. Food-related behavioral activation




































































































































































































































The boxplot inner horizontal lines represent the median, the boxes represent
the interquartile range (25% and 75%), the vertical whiskers represent the 1.5
interquartile range beyond the 25th and 75th percentiles, and the dots
represent all other values. The diamonds represent the means. The dark blue
bars indicate the intervention; the light blue bars, control. The No. of
participants represents the number of persons who completed the secondary
outcomes at the different time points. Data shown are the available data.
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therapy was significantly related to lower GAD scores at 12
months (adjusted mean difference, −0.48; 95% CI, −0.84 to
−0.12; P = .01). The unadjusted baseline GAD score for both the
therapy and nontherapy group was 5.8. At 12 months, the un-
adjusted score was 3.9 for the nontherapy group vs 3.2 for the
therapy group. No effect of therapy on other secondary out-
comes was found.
There was a significant effect of supplements on overall
follow-up measures of the PHQ (adjusted mean difference,
0.65; 95% CI, 0.25-1.06; P = .002), the IDS (adjusted mean
difference, 1.20; 95% CI, 0.29-2.10; P = .01), and the GAD (ad-
justed mean difference, 0.50; 95% CI, 0.16-0.84; P = .004)
scores. There was also a significant effect on PHQ scores at
the 12-month follow-up (adjusted mean difference, 0.56;
95% CI, 0.11-1.01; P = .02). The unadjusted baseline PHQ for
those taking placebo was 7.3 vs 7.5 for those taking supple-
ments. The unadjusted 12-month PHQ score for placebo was
4.1 vs 4.9 for supplements. This indicates less improvement
in depressive and anxiety symptoms for supplements relative
to placebo.
Effect Modification and Sensitivity Analyses
The eAppendix 10 in Supplement 3 shows the results of post
hoc effect modification analyses by study site, history of
depression, and baseline symptoms scores. These analyses
suggested that (1) the effect of food-related behavioral activa-
tion therapy on PHQ at 12 months was more favorable (larger
reduction) when the baseline PHQ depression severity was
higher, (2) the use of supplements resulted in higher
follow-up anxiety scores when the baseline anxiety severity
scores were higher, and (3) that the effect of food-related
behavioral activation on health utility scores at 12 months
was larger in the United Kingdom than in the Netherlands.
Sensitivity analyses for depression, anxiety, and health utility
scores without multiple imputed data gave comparable effect
estimates (eAppendix 11 in Supplement 3). The results of the
Complier Average Causal Effect (CACE) analyses were consis-
tent with the original analyses, finding no effect of supple-
ments on the primary outcome, and similar effects for sec-
ondary outcomes (eAppendix 12 in Supplement 3). The CACE
analyses found a significant effect of food-related behavioral
activation therapy on the primary outcome (OR, 0.78; 95%
CI, 0.64-0.95), accounting for treatment adherence.
Adverse Events and Concealment
Ninety-eight participants were hospitalized and 1 participant
died during the 12-month follow-up, these events were judged
as unrelated to interventions (eAppendix 8 in Supplement 3).
Those receiving placebo were less likely to believe they were
taking multinutrients than did those receiving multinutri-
ents (placebo without therapy, 8.2%; placebo with therapy,
10.4%; multinutrients without therapy, 25.5%; and multi-
nutrients with therapy, 43.7%; P < .001; eAppendix 13 in
Supplement 3). Of those completing the questions on conceal-
ment at the 12-month follow-up, 40.4% reported that they did
not know their allocation.
Table 3. Effect of Supplements and Food-Related Behavioral Activation Therapy on Secondary Outcomesa
Outcomes
Overall Follow-up Effect Using All Follow-upsb Effect at 12 Month Follow-upc
P Value Cohen D ValueeEstimate (95% CI)d P Value Estimate (95% CI)d
Patient Health Questionnaire 9
Supplements vs placebo 0.33 (0.12 to 0.53) .002 0.28 (0.05 to 0.50) .02 0.10
With vs without food-related
behavioral activation therapy
−0.13 (−0.33 to 0.07) .19 −0.17 (−0.39 to 0.06) .14 −0.02
Inventory of Depressive Symptomatology
Supplements vs placebo 0.60 (0.15 to 1.05) .01 0.36 (−0.19 to 0.90) .20 0.05
With vs without food-related
behavioral activation therapy
−0.23 (−0.67 to 0.22) .32 −0.28 (−0.83 to 0.27) .31 0.006
Generalized Anxiety Disorder 7
Supplements vs placebo 0.25 (0.08 to 0.42) .004 0.14 (−0.04 to 0.33) .13 0.10
With vs without food-related
behavioral activation therapy
−0.16 (−0.32 to 0.01) .06 −0.24 (−0.42 to −0.06) .01 −0.07
Utility
Supplements vs placebo −0.006 (−0.012 to 0.000) .052 −0.002 (−0.008 to 0.005) .61 −0.07
With vs without food-related
behavioral activation therapy
0.002 (−0.003 to 0.008) .44 0.004 (−0.002 to 0.009) .23 0.08
Abbreviation: estimate, unstandardized regression coefficient.
a The 2 interventions were modeled together. All models were adjusted
for study site, history of major depressive disorder, and for the baseline
value of the corresponding outcome measure. Food-related
behavioral activation therapy and pills were effect-coded (−1,1),
supplement × food-related activation interaction therapy interaction
effects were not included in the model because none of the interactions
were statistically significant.
b Estimates were obtained from generalized estimating equations
longitudinal (GEE) analyses using effect-coded interventions based on
multiple imputed data.
c Estimates were obtained from robust linear regression analyses based on
multiple imputed data.
d To obtain adjusted mean differences in outcomes between the intervention
conditions, the estimates and 95% CIs should be multiplied by 2.
e The Cohen D value was calculated from baseline and 12-month follow-up
means and pooled standard deviations obtained from multiple imputed data.
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Discussion
This multicenter trial involving 1025 overweight individuals
with subsyndromal depressive symptoms showed no effect
from multinutrient supplements, food-related behavioral ac-
tivation therapy, or their combination on the 1-year cumula-
tive onset of MDD.
To our knowledge, this is the first randomized trial evalu-
ating the effectiveness of 2 nutritional strategies and their com-
bination for the prevention of depression in a high-risk group
of overweight people. Despite the large sample size and selec-
tion of people with elevated depressive symptoms, the onset
of MDD was lower than expected, which reduced the statisti-
cal power to detect a statistically significant effect. Compari-
sons of intervention effects with other trials are difficult due
to methodological and sample differences. Compared with pre-
vious trials testing preventive psychological strategies for de-
pression that found significant effects,35 our sample had on av-
erage lower initial levels of depressive symptoms and lower
likelihood of having a history of MDD, making them less vul-
nerable to MDD onset.
The adherence to both interventions was adequate, with
about three-quarters fulfilling predefined adherence criteria for
the interventions. For food-related behavioral activation, the in-
dividual sessions in the first 6 months were well attended, but
the group sessions in the subsequent 6 months were not.
This study showed that multinutrient supplements con-
taining omega-3 PUFAs, vitamin D, folic acid, and selenium nei-
ther reduced depressive symptoms, anxiety symptoms, nor im-
proved health utility measures. In fact, they appeared to result
in slightly poorer depressive and anxiety symptoms scores
compared with placebo. Despite substantial evidence of ob-
servational studies linking lower nutrient levels to higher de-
pressive symptoms, similar to our findings, a review of 9 RCTs
found no support that vitamin D could prevent depression in
older adults.12 For omega-3 PUFAs, one RCT involving mild to
moderately depressed individuals—a population that is some-
what comparable with our sample—also showed no favorable
effect of omega-3 PUFAs on depressive symptoms.36 No ef-
fect of folic acid combined with vitamin B6 and B12 was found
on the onset of depression in older men37 and older women.38
Furthermore, Rayman et al39 found no effect of selenium on
mood in older adults. Overall, the studies available thus far,
including our trial, do not support the use of nutritional supple-
mentation in the prevention of depression.12
Food-related behavioral activation therapy had a signifi-
cant effect on reduction in anxiety symptoms at 12 months but
not on any of the other secondary mental health outcomes.
When accounting for a priori defined intervention adherence
(ie, attending ≥8 of 21 sessions), food-related behavioral acti-
vation therapy was related to lower MDD onset, with an ef-
fect size comparable with that reported in (meta-analytic) stud-
ies of psychological interventions for depression.28,35,40 In a
post hoc analysis, a more beneficial effect of food-related be-
havioral activation therapy on depressive symptoms for those
with higher baseline depression scores was observed. This sug-
gests that with sufficient dose and a higher-risk sample, food-
related behavioral activation therapy might prevent depres-
sion, although this requires further study. It would be relevant
to study which characteristics make participants more likely
to adhere to the intervention, to identify persons who may ben-
efit from it.
The strengths of this study are the randomized 2 × 2 fac-
torial design, the inclusion of participants from 4 countries with
different background characteristics and dietary patterns, the
large sample size compared with other prevention studies of
depression,35 the intervention and follow-up period of 1 year,
the efficient testing of multiple nutrients, the blinded design,
its measurement of multiple outcome assessments, and the ac-
tive adherence monitoring.
Limitations
This study has several limitations. First, the onset of MDD
was lower than expected, which resulted in lower power to
detect significant effects, if present. However, because pla-
cebo outperformed supplements for some secondary out-
comes, it is unlikely that inclusion of an adequately powered
sample would favor supplements for the prevention of
depression. Second, a considerable number of participants
(about a quarter) was lost to follow-up. Although this number
was balanced between intervention groups, attrition bias
cannot be ruled out. Third, those who received placebo were
less likely to believe they were taking multinutrients, which
suggests that the blinding of participants was not optimal.
Fourth, participants were not selected based on deficiencies
in the specific nutrients provided. It is conceivable that defi-
cient individuals will be more likely to benefit from supple-
mentation, but studies addressing this are scarce.12 Fifth, no
active control group for the food-related behavioral activa-
tion therapy component was present. Sixth, the predefined
follow-up time of this study was 1 year, which might have
been too short to detect an effect.
Conclusions
Among overweight or obese adults with subsyndromal de-
pressive symptoms, multinutrient supplementation com-
pared with placebo and food-related behavioral activation
therapy compared with no therapy did not reduce episodes of
major depressive disorder during 1 year. These findings do not
support the use of these interventions for prevention of ma-
jor depressive disorder in this population.
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